Document:

EXHIBIT 10.11

                               ADVISORY AGREEMENT

                  This ADVISORY AGREEMENT (this "Agreement"), effective as of
August 1, 2005, is by and between Valeo Partners LLC, and any of its affiliates,
having an address at 680 Fifth Avenue, 8th Floor, New York, NY 10019
(hereinafter referred to as "VALEO") and Cygene Laboratories, Inc., having
offices at 7786 Wiles Road, Coral Springs, FL 33067 (hereinafter referred to as
"CYGENE" or the "Company").

                              W I T N E S S E T H:

         WHEREAS, CYGENE desires that it be able to call upon the knowledge and
experience of VALEO for strategic and investment advisory services;

         WHEREAS, VALEO is willing to render such services to CYGENE on the
terms and conditions hereinafter set forth in this Agreement;

         NOW, THEREFOR, in consideration of the mutual covenants and agreements
hereinafter set forth, the parties hereby agree as follows:

         SECTION 1. TERM OF AGREEMENT. This Agreement shall be in effect for a
period of one (1) year from the date hereof and shall supersede the former
Advisory Agreement executed by both parties and dated July 3, 2004. The term of
this Agreement may be extended for consecutive periods of one year each upon the
written agreement of CYGENE and the VALEO.

         SECTION 2. SERVICES. During the term of this Agreement, VALEO shall
provide CYGENE with financial and strategic advice and other forms of assistance
in connection with proposed transaction(s), which may involve advice and
assistance in connection with defining strategic and financial objectives,
financing strategies and capital raises, identifying potential acquisitions,
buyers or investors, assisting in the preparation of related materials for
distribution to such entities, reviewing financial information and assisting in
negotiations of the financial terms and structure of the aforementioned
activities.

         VALEO, in its capacity as advisor, will perform the following financial
and strategic advisory services as CYGENE may reasonably request:

         (a)      VALEO will meet with the Company's management and familiarize
                  itself to the extent it reasonably deems necessary,
                  appropriate and feasible with the business, operations,
                  properties, financial condition and prospects of the Company
                  in order to better determine ways in which VALEO can
                  facilitate the Company's objectives;

         (b)      VALEO will advise and assist the Company in identifying and/or
                  evaluating various strategic alternatives that may be
                  available to the Company to enhance shareholder values,
                  including without limitation, a merger or consolidation or
                  other business combination involving the Company and one or
                  more third parties, a sale (whether or not the proposal
                  therefor is solicited or unsolicited) of the Company or a
                  significant portion of its equity securities, assets or
                  business to one or more third parties, a recapitalization or
                  restructuring of the Company (including divestitures,
                  spin-offs, split-offs and similar transactions), a liquidation
                  of the Company, an acquisition of all or a significant portion

<PAGE>

                  of the assets or equity securities of another corporation or
                  other business entity, or such other form of transaction that
                  VALEO, after completing the familiarization process provided
                  for in subparagraph 2(a) hereof, believes may be of possible
                  interest to the Company (each a "Strategic Transaction"). If
                  the Company determines to consider or undertake one or more
                  Strategic Transactions, VALEO will advise and assist the
                  Company in considering the desirability of undertaking such
                  Strategic Transaction(s) and, if the Company believes such
                  Strategic Transaction(s) to be desirable, in structuring and
                  effecting such Strategic Transaction(s);

         (c)      VALEO will also advise and assist the Company in identifying
                  and/or evaluating various financial options available in the
                  public and private equity and debt markets including, but not
                  limited to, primary issuance of common stock of the Company
                  (each a "Financing Transaction"). If the Company determines to
                  consider or undertake one or more Financing Transactions,
                  VALEO will advise and assist the Company in considering the
                  desirability of undertaking such Financing Transaction(s) (a
                  Strategic Transaction and a Financing Transaction are
                  sometimes collectively hereinafter referred to as a
                  "Transaction");

         (d)      VALEO shall assist the Company and the Company shall cooperate
                  with VALEO in the preparation of a detailed set of financial
                  projections, pro forma financial projections to evaluate
                  certain Transaction(s), any Information Memoranda or similar
                  documents in connection with any Strategic or Financing
                  Transaction; and

         (e)      VALEO will render such other financial advisory and related
                  services as may from time to time be agreed upon by VALEO and
                  the Company; provided however that VALEO's services hereunder
                  shall not be full-time and shall not be exclusive to the
                  Company although VALEO will devote such business time,
                  attention, efforts, skill and ability as VALEO at its sole
                  discretion deems to be necessary.

         If the Company requests VALEO to provide additional services not
otherwise contemplated by this Agreement, the Company and VALEO will enter into
an additional agreement which shall set forth the nature and scope of the
services, including without limitation, appropriate compensation, as mutually
agreed upon by the Company and VALEO.

SECTION 3. COMPENSATION. In consideration for the services performed in
connection with this Agreement, CYGENE will pay VALEO a monthly Advisory Fee
equal to $10,000 USD per month beginning August 1, 2005. In addition, CYGENE
shall issue to VALEO warrants to purchase 250,000 shares of the stock of CyGene
Laboratories, Inc. (CYGE.PK) at a $.25 strike price fully vesting upon 1-year
from the date of this agreement. The options will vest, monthly, on a pro-rated
basis.

         In addition, CYGENE agrees to pay VALEO the following fees:

         (i)      For any and all debt, mezzanine or non-equity Financing
                  Transaction(s) the Company engages in and that are originated
                  by VALEO, the Company agrees to pay VALEO a Debt Capital
                  Advisory Fee for such Transaction(s) equal to:

                  a.       5.00% of the first $10,000,000 in Transaction Value;

                  b.       4.00% of the Transaction Value from $10,000,001 to
                           $20,000,000;

                                       2
<PAGE>

                  c.       3.00% of the Transaction Value from $20,000,001 to
                           $30,000,000;

                  d.       2.00% of the Transaction Value from $30,000,001 to
                           $40,000,000; and

                  e.       1.00% of the Transaction Value above $40,000,000.

                  The Debt Capital Advisory Fee shall be paid in cash or
                  certified or bank check upon the closing date of a Transaction
                  if, during the term of this engagement or within 12 months
                  thereafter, a Transaction is consummated or an agreement is
                  entered into that subsequently results in a Transaction;
                  provided that this Debt Capital Advisory Fee shall be due to
                  VALEO only if the parties to the Transaction were directly or
                  indirectly introduced to CyGene by VALEO. VALEO may elect to
                  receive up to fifty percent (50.00%) of the Debt Capital
                  Advisory Fee in ownership stock or warrants of CYGENE in lieu
                  of cash.

         (ii)     For any and all equity, hybrid or equity-linked Financing
                  Transaction(s) the Company engages in and that are originated
                  by VALEO, the Company agrees to pay VALEO an Equity Capital
                  Advisory Fee for such Transaction(s) equal to:

                  a.       5.00% of the first $10,000,000 in Transaction Value;

                  b.       4.00% of the Transaction Value from $10,000,001 to
                           $20,000,000;

                  c.       3.00% of the Transaction Value from $20,000,001 to
                           $30,000,000;

                  d.       2.00% of the Transaction Value from $30,000,001 to
                           $40,000,000; and

                  e.       1.00% of the Transaction Value above $40,000,000.

                  The Equity Capital Advisory Fee shall be paid in cash or
                  certified or bank check upon the closing date of a Transaction
                  if, during the term of this engagement or within 12 months
                  thereafter, a Transaction is consummated or an agreement is
                  entered into that subsequently results in a Transaction;
                  provided that this Equity Capital Advisory Fee shall be due to
                  VALEO only if (A) the parties to the Transaction were directly
                  or indirectly introduced to CyGene by VALEO, or (B) VALEO at
                  the Company's request, provided substantive advisory services
                  concerning the structuring of the deal. VALEO may elect to
                  receive up to fifty percent (50.00%) of the Equity Capital
                  Advisory Fee in ownership stock or warrants of CYGENE in lieu
                  of cash.

         (iii)    If the event takes the form of a Strategic Transaction that
                  has been originated by VALEO, or if VALEO, at the Company's
                  request, provided substantive advisory services concerning the
                  structuring of a deal, CYGENE agrees to pay VALEO a
                  Transaction Fee equal to two and one half (2.5) percent of the
                  Transaction Value (as defined below), payable in cash and/or
                  CYGENE's common stock upon the closing date of a Strategic
                  Transaction if, during the term of this engagement or within
                  12 months thereafter, a Strategic Transaction is consummated
                  or an agreement is entered into that subsequently results in a
                  Strategic Transaction. This Transaction Fee shall be due to
                  VALEO only if (A) the parties to the Transaction were directly
                  or indirectly introduced to CyGene by VALEO, or (B) Valeo at
                  the Company's request, provided substantive advisory services
                  concerning the structuring of the deal.

                                       3
<PAGE>

                  As used in this Agreement, "Transaction Value" means the total
         value (on the date of payment) of all consideration (including cash,
         securities or other property) paid or received or to be paid or
         received, directly or indirectly, in connection with a Transaction with
         respect to the assets of the Target(s), plus the principal amount of
         any debt (including capitalized leases) of the Target(s) outstanding or
         assumed, refinanced or extinguished in connection with a Transaction,
         and amounts payable in connection with a Transaction with respect to
         employment or consulting agreements, agreements not to compete or
         similar arrangements. Fees on amounts paid into escrow will be payable
         upon the release of such funds. Fees relating to contingent payments
         other than escrowed amounts will be calculated based on the present
         value of the reasonably expected maximum amount of such contingent
         payments as determined in good faith by the CYGENE and VALEO prior to
         the closing of the Transaction, utilizing a discount rate equal to the
         prime rate published in the THE WALL STREET JOURNAL on the last
         business day preceding the closing of the Transaction.

         SECTION 4. EXPENSES. CYGENE will promptly reimburse VALEO for all
reasonable expenses incurred by VALEO in connection with its role hereunder,
which may include, but shall not be limited to, applicable travel, legal,
accounting, and due diligence related expenses, provided that the incurrence of
such expenses has been approved in advance by CyGene.

         SECTION 5. INSIDER TRADING. VALEO recognizes that in the course of its
duties hereunder, VALEO may receive from CYGENE or others information which may
be considered "material, nonpublic information" concerning a public company that
is subject to the reporting requirements of the Securities and Exchange Act of
1934, as amended. VALEO agrees NOT to:

                  (a) Buy or sell any security, option, bond or warrant while in
possession of material, nonpublic information received from CYGENE or others in
connection herewith;

                  (b) Provide CYGENE with information with respect to any public
company that may be considered material, nonpublic information; or

                  (c) Provide any person with material, nonpublic information,
received from CYGENE, including any relative, associate or other individual.

         SECTION 6. REPRESENTATIONS OF VALEO. VALEO represents that there are no
binding agreements to which it is a party or by which it is bound, forbidding or
restricting its activities herein. In addition, during the term of this
Agreement, VALEO consents to the use of its name in various reports, brochures
or other documents produced by or on behalf of or CYGENE.

         SECTION 7. SURVIVAL. The provisions of this Agreement relating to
confidentiality and insider trading shall survive any termination or expiration
hereof for three years.

         SECTION 8. VALEO NOT AN EMPLOYEE. CYGENE and the VALEO hereby
acknowledge and agree that VALEO shall perform the services hereunder as an
independent contractor and not as an employee of CYGENE.

         SECTION 9. INDEMNIFICATION. CYGENE shall defend and indemnify VALEO in
its capacity as an advisor to CYGENE against any and all claims, judgments,
damages, liabilities, costs and expenses (including reasonable attorney's fees)
arising out of, based upon or related to the VALEO's performance of services
hereunder, except to the extent that such claims arise out of willful
misfeasance or gross negligence, and subject to the provisions of Section 4.

                                       4
<PAGE>

         SECTION 10.  MISCELLANEOUS.

                  (a) Severability Of Provisions. If any provision of this
Agreement shall be declared by a court of competent jurisdiction to be invalid,
illegal or incapable of being enforced in whole or in part, the remaining
conditions and provisions or portions thereof shall nevertheless remain in full
force and effect and enforceable to the extent they are valid, legal and
enforceable, and no provision shall be deemed dependent upon any other covenant
or provision unless so expressed herein.

                  (b) Entire Agreement; Modification. This Agreement is the
entire agreement of the parties relating to the subject matter hereof and
thereof, and the parties hereto and thereto have made no agreements,
representations or warranties relating to the subject matter of this Agreement
which are not set forth herein or therein. No amendment or modification of this
Agreement shall be valid unless made in writing and signed by each of the
parties hereto.

                  (c) Binding Effect. The rights, benefits, duties and
obligations under this Agreement shall inure to, and be binding upon, the
Company, its successors and assigns, and upon VALEO. This Agreement constitutes
a personal service agreement, and the performance of VALEO's obligations
hereunder may not be transferred or assigned by VALEO and any such purported
transfer or assignment shall null and void ab initio.

                  (d) Third Party Beneficiaries. This Agreement is for the
benefit of the parties hereto and their permitted successors and assigns, and is
not intended to confer upon any other person or entity, any rights or remedies
hereunder.

                  (e) Non-Waiver. The failure of either party to insist upon the
strict performance of any of the terms, conditions and provisions of this
Agreement shall not be construed as a waiver or relinquishment of future
compliance therewith, and said terms, conditions and provisions shall remain in
full force and effect. No waiver of any term or condition of this Agreement on
the part of either party shall be effective for any purpose whatsoever unless
such waiver is in writing and signed by such party.

                  (f) Governing Law. This Agreement shall be governed by, and
construed and interpreted in accordance with, the laws of the State of New York
without regard to such State's principles of conflict of laws. The parties
irrevocably and unconditionally agree that any action whatsoever arising out of
this Agreement and/or the rights of the parties hereto or hereunder (the
"Actions") shall be brought only in the courts located in New York County in the
State of New York. Each party irrevocably and unconditionally waives any
objection it may have to the venue of any Action brought in such courts or to
the convenience of the forum. Final judgment in any such Action shall be
conclusive and may be enforced in other jurisdictions by suit on the judgment, a
certified or true copy of which shall be conclusive evidence of the fact and the
amount of any indebtedness or liability of any party therein described.

                  (g) Headings. The headings of the Sections are inserted for
convenience of reference only and shall not affect any interpretation of this
Agreement.

                                       5
<PAGE>

                  IN WITNESS WHEREOF, the parties hereto have executed this
Agreement by proper person thereunto duly authorized.

                                        CYGENE LABORATORIES, INC.

                                        -----------------------------
                                        By:      Martin Munzer
                                        Title:   CEO
                                        Date:    August 1, 2005

                                        VALEO PARTNERS LLC

                                        -----------------------------
                                        By:      Frank RoccoGrande
                                        Title:   Partner
                                        Date:    August 1, 2005

                                       6EXHIBIT 10.12

                                  [CyGene LOGO]

                              CONSULTING AGREEMENT

Agreement, dated as of 12-08-2005, between Dx Innovations, Inc. (3935 Lago di
Grata Cir., San Diego, CA 92130; hereafter Dx Innovations) and CyGene, Inc.
(hereinafter CyGene), having principal place of business at:

                  7786 Wiles Road
                  Coral Springs, FL 33067

CyGene, Inc. desires to retain the services of Dx Innovations in a consulting
capacity with respect to certain activities as described in Exhibit A, and Dx
Innovations is willing to so act.

NOW, THEREFORE, Dx Innovations and CyGene agree as follows:

1.   Description of Services. CyGene hereby retains Dx Innovations as to perform
     the following services for CyGene:

     a)  An estimated 40 hours per month consultation with CyGene's scientist or
         management or as otherwise designated by CyGene, in the form of formal
         meetings or consultation.

     b)  Dx Innovations may from time to time be unavailable to attend formal
         meetings or perform other consulting duties that are not in conflict
         with or competitive to the business activities of CyGene, and such
         unavailability shall not be considered a breach of this AGREEMENT.

     c)  Dx Innovations' consultation will involve the specialized field of
         molecular biology and requires the application of the unique, special
         and extraordinary skills and knowledge that Dx Innovations possesses in
         this area.

2.   Term and Expiration. This Agreement shall become effective as of the date
     hereof and remain in effect for six (6) months. In rendering services to
     CyGene, Dx Innovations shall act as an independent contractor and not as an
     employee or agent of CyGene.

3.   Compensation. For all services provided hereunder, CyGene will pay Dx
     Innovations a fee of $250 per hour. Payment will be made in cash and CyGene
     common stock as outlined in Exhibit B. Payments will be made in arrears, on
     a weekly billing basis or as otherwise agreed upon by both parties.

4.   Expenses. CyGene will reimburse Dx Innovations for any actual expenses
     incurred by Dx Innovations while rendering services under this Agreement so
     long as the expenses are reasonable and necessary, upon prior written
     approval by CyGene. Such expenses shall include reasonable and necessary
     travel, lodging and meals in connection with services performed under this
     Agreement. Requests for reimbursement shall be in a form reasonably
     acceptable to CyGene.

                                   Page 1 of 5
                                               Dx Innovations - CyGene Agreement

<PAGE>
                                  [CyGene LOGO]

5.   Proprietary Information and Patents. Dx Innovations understands and agrees
     that CyGene possesses and will continue to possess information that has
     been created, discovered, or developed, or has otherwise become known to
     CyGene, including information made known to or created, discovered, or
     developed by Dx Innovations, arising out of its retention as a consulting
     firm by CyGene, which information has commercial value in the business in
     which CyGene is engaged. All of the aforementioned information is
     hereinafter called "Proprietary Information." By way of illustration, but
     not limitation, Proprietary Information includes trade secrets, processes,
     formulae, data and know-how, improvements, inventions, techniques, planned
     products, research and development, marketing plans, business plans,
     strategies, forecasts, customer lists, confidential information about
     finances, marketing, pricing, costs or compensation.

              a)  All Proprietary Information shall be the sole property of
                  CyGene and its assigns, and CyGene and its assigns shall be
                  the sole owner of all patents and other rights in connection
                  therewith. At all times during its retention as a consulting
                  firm for CyGene and at all times after termination of such
                  retention as a consulting firm, Dx Innovations will keep in
                  confidence and trust all Proprietary Information, and will not
                  use for its own account (or for the benefit of any person or
                  entity), or disclose any Proprietary Information or anything
                  relating to it without the written consent of CyGene, except
                  as may be necessary in the ordinary course of performing its
                  duties as a consultant of CyGene.

              b)  All documents, data, records, apparatus, equipment and other
                  physical property, whether or not pertaining to Proprietary
                  Information, furnished to Dx Innovations by CyGene or produced
                  by Dx Innovations or others in connection with Dx Innovations'
                  retention shall be and remain the sole property of CyGene and
                  shall be returned promptly to CyGene as and when requested by
                  CyGene. Should CyGene not so request, Dx Innovations shall
                  return and deliver all such property upon termination of its
                  retention as a consulting firm for any reason, and Dx
                  Innovations will not retain any such property or reproduction
                  of such property upon such termination.

              c)  Subject to the provisions of Article 7. Dx Innovations will
                  promptly disclose and assign to CyGene, or any persons
                  designated by it, all improvements, inventions, formulae,
                  processes, techniques, know-how and data, whether or not
                  patentable, (collectively hereinafter called "INVENTIONS")
                  made or conceived or reduced to practice by Dx Innovations,
                  either alone or jointly with others, during the period of its
                  retention as a consultant which (i) result from tasks assigned
                  to Dx Innovations by CyGene, or (ii) result from use of
                  premises owned, leased or contracted for by CyGene All
                  INVENTIONS shall be the sole property of CyGene and its
                  assigns, including all patents and other proprietary rights in
                  connection therewith. Dx Innovations agrees to execute all
                  documents and take all actions necessary to assign and
                  transfer the foregoing to CyGene.

              d)  Dx Innovations' scientists may freely publish any results of
                  its work covered under the Agreement, provided that prior U.S.
                  patent application is made on any potentially patentable
                  aspects of its work. Dx Innovations agrees to provide CyGene
                  with sufficient disclosure not less than 120 days prior to
                  publication, to allow CyGene to have patent applications
                  prepared on inventions or other information made or acquired

                                   Page 2 of 5
                                               Dx Innovations - CyGene Agreement

<PAGE>
                                  [CyGene LOGO]

                  under this agreement of potential commercial value. CyGene
                  agrees to keep all such disclosures confidential prior to
                  publication.

              e)  Nothing in this Agreement shall transfer to CyGene any rights
                  to INVENTIONS that are owned or are provided to Dx Innovations
                  by third parties for research purposes.

6.   Governing Law. This Agreement shall be governed and construed in accordance
     with the laws of the State of Florida.

7.   No Conflict. Dx Innovations represents that its performance of all the
     terms of this Agreement and that its retention as an advising firm to
     CyGene does not and will not breach any agreement to keep in confidence
     proprietary information acquired by Dx Innovations in confidence or in
     trust prior to its retention as an advising firm by CyGene Dx Innovations
     has not entered into, and agrees he will not enter into, any agreement,
     either written or oral, in conflict herewith. Dx Innovations understands as
     part of the consideration for the offer to retain it as an advising firm,
     and of its retention as an advising firm by CyGene, that it has not brought
     and will not bring to CyGene or use in the performance of its
     responsibility at CyGene any equipment, supplies, facility or trade secret
     information of any current or former clients which are not generally
     available to the public, unless Dx Innovations has obtained written
     authorization for their possession and use. Dx Innovations also understands
     that, in its retention as an advising firm of CyGene, it is not to breach
     any obligation of confidentiality that it has to others, and it agrees that
     it shall fulfill all obligations during its retention as an advising firm
     with CyGene.

8.   Successors, etc. This Agreement shall be binding upon and shall inure to
     the benefit of CyGene's successors, transferees, and assigns.

9.   This agreement can be terminated by either party within 30 days written
     notice.

IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the
day and year written below.

   For CYGENE, INC.:

   ______________________________                    __________________
   Martin Munzer, President & CEO                         Date

   For DX INNOVATIONS, INC.:

   ________________________________                  __________________
   Andreas Braun PhD, MD, President                       Date

                                   Page 3 of 5
                                               Dx Innovations - CyGene Agreement

<PAGE>
                                  [CyGene LOGO]

                                    Exhibit A

CyGene, Inc. engages Dx Innovations, Inc as a consulting firm to:

1)     Review and edit current and future testing result report forms for
       CyGene's direct to consumer DNA testing business
2)     suggest improvements of testing panels and report generating algorithms
3)     translate report forms into German for test results report generation and
       marketing of CyGene's test panels in Germany and Europe
4)     assist CyGene in its business and product development efforts
5)     advise and assist in ongoing and future Haystack Processing technology
       developments.

CyGene will provide literature that was central for developing report
algorithms.

                                   Page 4 of 5
                                               Dx Innovations - CyGene Agreement

<PAGE>
                                  [CyGene LOGO]

                                    Exhibit B

Payment schedule: 25% of billed invoice shall be paid in cash and the remaining
75% are payable in restricted shares of common stock at a 50% discount from the
market price based on the ten day prior closing average of CYGE stock, when the
invoice is presented. There is a $0.25 minimum price to any issuances of stock.

                                   Page 5 of 5
                                               Dx Innovations - CyGene Agreement

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00104-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00104-of-00352.parquet"}]]